tbuckley/cabot-search huggingface dataset:
CMV retinitis.
Authors: H W Murray
Journal: BMJ (1976)

and his Addison's disease might have been induced therefore by sarcoidosis rather than by "idiopathic" adrenal failure.If so, his wife could have contracted one or other of these diseases herself subclinically.The prolonged cellular immunity generated by sarcoidosis might have cven triggered off her mammary carcinoma.! Was raised immunity then responsible for the other malignancies in this family?A few tuberculous parents have had children who later developed sarcoidosis.The son in this family was found much later to have the coeliac syndrome.Was this also caused by the sarcoid agent?'The answers to these questions are still unknown because not enough facts are yet available.But it is unlikely in the meantime that natural selection will eliminate the sarcoid agent.
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
Authors: Satoshi Yasuda, Koichi Kaikita, Masaharu Akao, Junya Ako, Tetsuya Matoba, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa
Journal: New England Journal of Medicine (2019)

There are limited data from randomized trials evaluating the use of antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease.
Testosterone replacement therapy in men with prostate cancer after proton therapy.
Authors: Curtis Bryant, Bradford S. Hoppe, Nancy P. Mendenhall, Randal H. Henderson, Romaine Charles Nichols, Christopher G. Morris, Christopher R. Williams, Zhong Su, Zuofeng Li, William M. Mendenhall
Journal: Journal of Clinical Oncology (2014)

208 Background: Testosterone replacement therapy (TRT) in patients previously treated for prostate cancer is controversial. We analyzed biochemical relapse and sexual function in patients treated for prostate cancer with proton therapy (PT) at our institution who were later treated with TRT for hypogonadism. Methods: We reviewed the medical records of 27 patients with biopsy-proven, localized prostate cancer treated with definitive proton therapy (PT) at our institution between 2006 and 2012. Each patient had hypogondal symptoms and low-serum testosterone and received testosterone replacement after PT. Biochemical failure was defined by the Phoenix definition. Sexual function was reported using patient-reported data from the Expanded Prostate Cancer Index Composite (EPIC) questionnaire. Rates of sexual potency were also reported. Results: Twenty-three patients were included in the present analysis. The median follow-up duration was 38 months after PT and 14 months after initiation of TRT. After one to six months on TRT, the median serum testosterone level in this patient cohort increased from 238 to 497. No patient experienced a biochemical failure. The median prostate-specific antigen (PSA) did not significantly rise during the follow-up period. EPIC sexual summary, sexual function, and sexual bother scores all increased after initiation of TRT. The median sexual bother scores increased from 43.8 before TRT to 59.4 after 7 or more months of TRT. The median sexual summary scores improved from 50 to 61.8 and the median sexual function scores improved from 41.7 to 53 over the same time. Sexual potency also increased after TRT initiation from 50% to 68%, 7 or more months after TRT. Conclusions: For patients diagnosed with hypogonadism who were previously treated for prostate cancer, cautious use of testosterone replacement therapy does not appear to increase the risk of biochemical failure or increase PSA. Sexual function may improve to approximate pre-radiation levels in some cases. A prospective trial with long-term follow up is required to better support our findings.
Isolated systolic hypertension in the elderly
Authors: M. A. Winker
Journal: JAMA (1991)

Isolated systolic hypertension (ISH) affects up to two thirds of all individuals with hypertension between the ages of 65 and 89 years,<sup>1</sup>and its prevalence, as estimated by the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study, ranges from 6% of individuals aged 60 through 69 years to 18% of those aged 80 years or older.<sup>2</sup>This extremely common disease is an independent risk factor for the development of cerebrovascular and cardiovascular morbidity and mortality, and, in the Framingham Study, it was the single greatest risk factor other than age for the development of cardiovascular disease in the elderly population.<sup>3</sup> Isolated systolic hypertension is believed to result from the pathophysiology of aging, which includes decreased connective tissue elasticity and atherosclerosis, resulting in increased peripheral vascular resistance,<sup>4</sup>and diminished β<sub>2</sub>receptor sensitivity, leading to decreased smooth muscle relaxation.<sup>5</sup>Because of the presumed irreversible "stiffening"
The Retrospect of Medicine; a Half-yearly Journal containing a Retrospective View of every Discovery and practical Improvement in Medical Science.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease—Reply
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Poetry by Physicians
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hearing Loss
Authors: Anne Pitkin
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The practice and ethics of risk-rated health insurance
Authors: D. W. Light
Journal: JAMA (1992)

Health insurance in the United States is driven by competitive risk rating and is promoted as the best way to give policyholders optimal value for their money and to be fair to those with lower risks. In practice, however, competitive risk rating costs more than noncompetitive, universal systems of health insurance, and it erodes the basic function of insurance to spread infrequent large losses over a wide base. This article describes not only how risk rating covers least those with the greatest medical bills, but also how it has spawned a labyrinth of complex manipulations by insurance companies to charge more or pay less than actuarially fair risk rating would justify. The final section shows that even if risk rating were done fairly, it contradicts moral fairness. Many of the leading proposals for national health insurance do not address these practical and ethical issues. The medical profession and policymakers need to discuss them and take a stand on them. (JAMA. 1992;267:2503-2508)
Editorial: Psychiatry in military services
Authors: H. H. Hussey
Journal: JAMA (1974)

Back-to-back articles in the March issue of<i>Archives of General Psychiatry</i>, explore the psychosocial perspective of first-termers in the armed services and an ethical dilemma for military psychiatrists.<sup>1,2</sup>Mirin,<sup>1</sup>the author of the first article, spent a year as a member of a multidisciplinary "assistance team" attached to USAF Headquarters and having two officers each from the Medical Corps (psychiatry), the Staff Judge Advocate Office, the Chaplaincy, the Office of Information, and the Directorate of Personnel. Since the team operated as a mobile consulting service worldwide, Mirin had abundant opportunity to observe actions and activities at dozens of military installations. Mirin notes that the young, low-ranking, enlisted men are most likely to fail in adjustment to military life. On that point, he quotes Friedman.<sup>3</sup> Their backgrounds include broken homes, poverty and emotional... deprivation.... There are usually gross signs of poor adjustment prior to entry in the military....
Nonoxynol 9 and Octoxynol
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endothelin-1 (ET-1) enhances bile canalicular contractions in primary culture - involvement of intracytoplasmic free calcium ion and Ca++-ATPase activity 1) Dept. of Internal Medicine &amp; 2) Laboratory of Pathology Kitasato Institute Medical Center Hospital, Saitama 3) Dept. of Internal Medicine, School of Medicine, Keio University, Tokyo
Journal: Hepatology (1995)
Coexistent multiple myeloma and primary hyperparathyroidism
Authors: M. J. Stone
Journal: JAMA (1982)

A patient with multiple myeloma and hypercalcemia responded to cytotoxic chemotherapy. However, hypercalcemia persisted. Because of the absence of lytic bone lesions, the presence of a low serum phosphate level, and a family history of possible primary hyperparathyroidism, the patient was evaluated for this disorder. Serum parathyroid hormone and urinary cyclic adenosine monophosphate levels were elevated. Exploration of the neck disclosed two enlarged parathyroid glands (1,850 mg and 210 mg), which were excised. After surgery, the patient's serum calcium levels remained normal for one year. Progressive myeloma bone disease developed that eventually resulted in recurrent hypercalcemia and death. Autopsy revealed only evidence of myeloma. (<i>JAMA</i>1982;247:823-824)
ANNUAL EXHIBIT OF THE PATHOLOGICAL SOCIETY OF PHILADELPHIA.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
WHY, OH WHY, DID HE DIE?
Authors: Sigmund L. Wilens
Journal: JAMA (1964)

For 30 years as a practicing pathologist, I have been trying to supply the answers to the perpetual question, "Why did he die?" It has become most fatiguing. The conscientious clinician very dutifully inquires after the autopsy findings. I may show him a Pandora's box full of pathology: ruptured viscera, infected and torn heart valves, thrombosed arteries, widespread cancer, or a peritoneum filled with exudate. "I know all that," says the earnest clinician with a tone registering anything from mild reproof to utter disdain, "but why did he die?" Eventually this proves very bad for my disposition. In the good old days things were much more amiable. Oh, for the scientific subterfuges of yesteryear when the pathologist could say, "The patient died of 'fatty degeneration of the heart' or 'edema of the brain'." If he kept a dignified demeanor, his indifferently informed inquisitor might be satisfied. There was the big
Hematopoietic Stem Cells Encoding Porcine Factor VIII Induce Pro-coagulant Activity in Hemophilia A Mice with Pre-existing Factor VIII Immunity
Authors: Christopher B Doering, Bagirath Gangadharan, Hillary Z Dukart, H Trent Spencer
Journal: Molecular Therapy (2007)

The development of inhibitory antibodies directed against factor VIII (fVIII) remains the most significant clinical complication associated with the treatment of hemophilia A. Recently, we demonstrated that transplantation of genetically modified hematopoietic stem cells containing a high-expression porcine fVIII transgene promoted sustained high-level fVIII expression in naïve hemophilia A mice. In the current study, a similar gene transfer strategy was tested in hemophilia A mice harboring clinically significant anti–human factor VIII (anti-hfVIII) inhibitory antibody titers. Although the majority of mice contained circulating antibodies that cross-reacted with and inhibited porcine fVIII activity, transplantation of genetically modified hematopoietic stem cells containing a porcine fVIII transgene into myeloablated hemophilia A mice induced high-level fVIII activity. Furthermore, anti-hfVIII antibody titers steadily declined throughout the course of the study. However, non-myeloablative transplantation conditioning resulted in only partial success. No correlation between pre-transplantation antibody titers and post-transplantation fVIII activity levels or donor cell engraftment was observed. These data suggest that hematopoietic stem cell transplantation–based gene therapy incorporating a high-expression porcine fVIII transgene can be utilized successfully to treat hemophilia A patients harboring anti-hfVIII inhibitors. The development of inhibitory antibodies directed against factor VIII (fVIII) remains the most significant clinical complication associated with the treatment of hemophilia A. Recently, we demonstrated that transplantation of genetically modified hematopoietic stem cells containing a high-expression porcine fVIII transgene promoted sustained high-level fVIII expression in naïve hemophilia A mice. In the current study, a similar gene transfer strategy was tested in hemophilia A mice harboring clinically significant anti–human factor VIII (anti-hfVIII) inhibitory antibody titers. Although the majority of mice contained circulating antibodies that cross-reacted with and inhibited porcine fVIII activity, transplantation of genetically modified hematopoietic stem cells containing a porcine fVIII transgene into myeloablated hemophilia A mice induced high-level fVIII activity. Furthermore, anti-hfVIII antibody titers steadily declined throughout the course of the study. However, non-myeloablative transplantation conditioning resulted in only partial success. No correlation between pre-transplantation antibody titers and post-transplantation fVIII activity levels or donor cell engraftment was observed. These data suggest that hematopoietic stem cell transplantation–based gene therapy incorporating a high-expression porcine fVIII transgene can be utilized successfully to treat hemophilia A patients harboring anti-hfVIII inhibitors.
Gliflozins and reducing cardiovascular events . . . and other stories
Journal: BMJ (2017)

reduction in heart failure and cardiovascular death from all drugs in the SGLT-2i class" referred to the CVD-REAL study (http://circ.ahajournals.org/content/early/2017/05/16/CIRCULATIONAHA.117.029190).Randomised controlled trials to establish the cardiovascular effects of dapagliflozin have not yet reached completion.
Effect of Chloroquine and a Placebo on Warts
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Complications of artificial heart valves
Authors: F. E. Kloster
Journal: JAMA (1979)

DESPITE continuing advances in cardiac valve surgery, it remains clear that valve replacement with any prosthesis is a palliative and not a curative procedure.<sup>1</sup>Every patient with an artificial heart valve is subject to an ongoing risk of a variety of complications that vary with different prostheses but that are common to most. Follow-up studies report that nearly half of all patients surviving valve replacement are dead or have experienced serious complications by ten years after operation.<sup>2</sup>Meticulous medical management and a clear understanding of the more common problems with artificial valves are crucial in avoiding complications or in recognizing them early for prompt and appropriate care. <h3>Infectious Endocarditis</h3> Prosthetic-valve endocarditis is a continuing and life-threatening risk in patients with artificial heart valves. A valve prosthesis increases the patient's vulnerability to endocarditis and makes eradication of the infection difficult. Prosthetic endocarditis occurring early after operation (within 60 days)
Black student recruitment at the University of Washington
Authors: A. G. Swanson
Journal: JAMA (1969)

As a state university with a long-stated tradition of offering equal opportunity to all qualified students, the University of Washington granted the MD degree to two black students during the first 20 years of its medical school's history. It is impossible to tell how many black students applied and were rejected, for existing records give no evidence of race. Recognizing that conventional recruiting and admissions policies were not adequate to attract black students into medicine, an active program of counseling and information dissemination was started in 1968. The first major step was taken when the admissions officers of the School of Medicine and the School of Dentistry asked the black physicians and dentists of the Puget Sound area to begin a series of meetings. In these meetings the problems of motivation and counseling of black students enrolled in undergraduate programs on our own university campus were identified. These students had